|Lymphoproliferative disorder| | | |
|Rituximab is conditionally recommended over other DMARDs for patients who have a previous lymphoproliferative disorder for which rituximab is an approved treatment and who have moderate-to-high disease activity.|Very low|PICO 75 and PICO 76|p. 446â€“7|
|Hepatitis B infection| | | |